The Market Reports

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Gene Replacement Therapy
1.2.3 Gene Silencing Therapy
1.2.4 Gene Editing Therapy
1.2.5 Enzyme Replacement Therapy
1.3 Market by Application
1.3.1 Global Gene Therapy for Neurodegenerative Diseases Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals and Clinics
1.3.3 Research Institutions
1.3.4 Biotechnology Companies
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Therapy for Neurodegenerative Diseases Market Perspective (2018-2029)
2.2 Gene Therapy for Neurodegenerative Diseases Growth Trends by Region
2.2.1 Global Gene Therapy for Neurodegenerative Diseases Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Gene Therapy for Neurodegenerative Diseases Historic Market Size by Region (2018-2023)
2.2.3 Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Region (2024-2029)
2.3 Gene Therapy for Neurodegenerative Diseases Market Dynamics
2.3.1 Gene Therapy for Neurodegenerative Diseases Industry Trends
2.3.2 Gene Therapy for Neurodegenerative Diseases Market Drivers
2.3.3 Gene Therapy for Neurodegenerative Diseases Market Challenges
2.3.4 Gene Therapy for Neurodegenerative Diseases Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Therapy for Neurodegenerative Diseases Players by Revenue
3.1.1 Global Top Gene Therapy for Neurodegenerative Diseases Players by Revenue (2018-2023)
3.1.2 Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Players (2018-2023)
3.2 Global Gene Therapy for Neurodegenerative Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gene Therapy for Neurodegenerative Diseases Revenue
3.4 Global Gene Therapy for Neurodegenerative Diseases Market Concentration Ratio
3.4.1 Global Gene Therapy for Neurodegenerative Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy for Neurodegenerative Diseases Revenue in 2022
3.5 Gene Therapy for Neurodegenerative Diseases Key Players Head office and Area Served
3.6 Key Players Gene Therapy for Neurodegenerative Diseases Product Solution and Service
3.7 Date of Enter into Gene Therapy for Neurodegenerative Diseases Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Therapy for Neurodegenerative Diseases Breakdown Data by Type
4.1 Global Gene Therapy for Neurodegenerative Diseases Historic Market Size by Type (2018-2023)
4.2 Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Type (2024-2029)
5 Gene Therapy for Neurodegenerative Diseases Breakdown Data by Application
5.1 Global Gene Therapy for Neurodegenerative Diseases Historic Market Size by Application (2018-2023)
5.2 Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
6.2 North America Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023)
6.4 North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
7.2 Europe Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023)
7.4 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
8.2 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2023)
8.4 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
9.2 Latin America Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023)
9.4 Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
10.2 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023)
10.4 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Voyager Therapeutics
11.1.1 Voyager Therapeutics Company Detail
11.1.2 Voyager Therapeutics Business Overview
11.1.3 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Introduction
11.1.4 Voyager Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.1.5 Voyager Therapeutics Recent Development
11.2 Uniqure N.V.
11.2.1 Uniqure N.V. Company Detail
11.2.2 Uniqure N.V. Business Overview
11.2.3 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Introduction
11.2.4 Uniqure N.V. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.2.5 Uniqure N.V. Recent Development
11.3 Axovant Gene Therapies
11.3.1 Axovant Gene Therapies Company Detail
11.3.2 Axovant Gene Therapies Business Overview
11.3.3 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Introduction
11.3.4 Axovant Gene Therapies Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.3.5 Axovant Gene Therapies Recent Development
11.4 Novartis Ag
11.4.1 Novartis Ag Company Detail
11.4.2 Novartis Ag Business Overview
11.4.3 Novartis Ag Gene Therapy for Neurodegenerative Diseases Introduction
11.4.4 Novartis Ag Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.4.5 Novartis Ag Recent Development
11.5 Amicus Therapeutics
11.5.1 Amicus Therapeutics Company Detail
11.5.2 Amicus Therapeutics Business Overview
11.5.3 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Introduction
11.5.4 Amicus Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.5.5 Amicus Therapeutics Recent Development
11.6 Regenxbio Inc.
11.6.1 Regenxbio Inc. Company Detail
11.6.2 Regenxbio Inc. Business Overview
11.6.3 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Introduction
11.6.4 Regenxbio Inc. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.6.5 Regenxbio Inc. Recent Development
11.7 Sarepta Therapeutics
11.7.1 Sarepta Therapeutics Company Detail
11.7.2 Sarepta Therapeutics Business Overview
11.7.3 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Introduction
11.7.4 Sarepta Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.7.5 Sarepta Therapeutics Recent Development
11.8 Gensight Biologics
11.8.1 Gensight Biologics Company Detail
11.8.2 Gensight Biologics Business Overview
11.8.3 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Introduction
11.8.4 Gensight Biologics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.8.5 Gensight Biologics Recent Development
11.9 Krystal Biotech
11.9.1 Krystal Biotech Company Detail
11.9.2 Krystal Biotech Business Overview
11.9.3 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Introduction
11.9.4 Krystal Biotech Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.9.5 Krystal Biotech Recent Development
11.10 Avexis
11.10.1 Avexis Company Detail
11.10.2 Avexis Business Overview
11.10.3 Avexis Gene Therapy for Neurodegenerative Diseases Introduction
11.10.4 Avexis Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.10.5 Avexis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details